Results 31 to 40 of about 19,563 (105)

In vitro susceptibility of nonfermenting Gram-negative rods tomeropenem–vaborbactam and delafloxacin Suppl. Table 1

open access: yes, 2023
Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with
Thomas Guillard (12633958)   +11 more
core   +1 more source

Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date

open access: yesInfection and Drug Resistance, 2023
Fischer Herald,1 Rodrigo M Burgos1,2 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA; 2Department of Medicine, College of Medicine, University of Illinois Chicago, Chicago, IL, USACorrespondence ...
Herald F, Burgos RM
doaj  

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

open access: yesInfectious Diseases and Therapy, 2018
Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Richard G. Wunderink   +22 more
doaj   +1 more source

Activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates in Iran [PDF]

open access: yes, 2022
We evaluated the activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates.
Nikkhahi, Farhad   +16 more
core   +1 more source

Meropenem-Vaborbactam as salvage therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3 [PDF]

open access: yes, 2021
A 68-year-old man had recurrent bacteremia by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae resistant to ceftazidime-avibactam and cefiderocol.
Simona Barnini   +7 more
core   +2 more sources

Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

open access: yes, 2022
Introduction: The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin.
Giamarellos-Bourboulis, E.J.   +2 more
core   +1 more source

Mutation of kvrA causes OmpK35/36 porin downregulation and reduced meropenem/vaborbactam susceptibility in KPC-producing Klebsiella pneumoniae [PDF]

open access: yes, 2020
Meropenem/vaborbactam resistance in Klebsiella pneumoniae is associated with loss of function mutations in the OmpK35 and OmpK36 porins. Here we identify two previously unknown loss of function mutations that confer cefuroxime resistance in K. pneumoniae.
Avison, Matthew B   +5 more
core   +1 more source

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital

open access: yesMicrobiologia Medica, 2022
Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria.
Giuseppina Amarù   +6 more
doaj   +1 more source

Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model

open access: yesAntimicrobial Agents and Chemotherapy
Meropenem/vaborbactam is a preferred treatment option for KPC-producing Klebsiella pneumoniae (KPC-Kp) infections, but clinical cure rates remain suboptimal when it is used alone.
Nidhi Singh   +13 more
doaj   +1 more source

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

open access: yesAntibiotics, 2021
The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients.
Ruiying Han   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy